Please assess the completion status of the following clinical trial:

Trial Title: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First renal transplant~* Participant eligible to receive valganciclovir prophylaxis as determined by the treating physician in accordance with the local approved product prescribing information (Cohort A only) or the participant is not expected to require any valganciclovir prophylaxis (Cohort B only) post-transplant~* Participant has no history of known infertility~* Participant is able and willing to provide semen samples~* Participant agrees to utilize a barrier contraceptive throughout the study or for at least 90 days after cessation of valganciclovir treatment~Exclusion Criteria:~* Prior ganciclovir or valganciclovir within 3 months of enrollment~* Organ transplant other than kidney~* Participant has received an investigational new drug in the 3 months prior to transplant~* Participant hs received an alkylating agent or other medications known to affect fertility/spermatogenesis~* Participant is unlikely to be available for follow-up for the entire duration of the study (up to 52 weeks)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: Partcipants who Received Valganciclovir (Type: EXPERIMENTAL): Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
- Cohort B: Untreated Participants (Type: NO_INTERVENTION): Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).